<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

KPC Homograft Models for PDAC I/O Efficacy Studies

Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate and remains one of the most difficult to treat cancer types, with very few standard of care options. Investigators are keen to trial immunotherapies and combination immuno-oncology regimens for PDAC, and therefore require appropriate immunocompetent preclinical models.